Australia markets open in 27 minutes
  • ALL ORDS

    7,350.60
    +24.40 (+0.33%)
     
  • AUD/USD

    0.7033
    +0.0001 (+0.02%)
     
  • ASX 200

    7,112.50
    +19.50 (+0.27%)
     
  • OIL

    113.79
    +1.39 (+1.24%)
     
  • GOLD

    1,812.30
    -6.60 (-0.36%)
     
  • BTC-AUD

    43,398.38
    +432.53 (+1.01%)
     
  • CMC Crypto 200

    677.94
    +435.26 (+179.36%)
     

Gilead Sciences to Present at Upcoming Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FOSTER CITY, Calif., November 18, 2021--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:

Evercore ISI Annual HealthCONx Conference on Thursday, December 2 at 2:40pm ET

The live webcast can be accessed at the company’s investors page at investors.gilead.com. The replay will be available for at least 30 days following the presentation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005065/en/

Contacts

Jacquie Ross, Investors
Investor_relations@gilead.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting